DoD awards $2.4M for molecular testing reagents, with limited competition and potential for price increases

Contract Overview

Contract Amount: $2,398,990 ($2.4M)

Contractor: Cepheid

Awarding Agency: Department of Defense

Start Date: 2021-10-01

End Date: 2026-09-30

Contract Duration: 1,825 days

Daily Burn Rate: $1.3K/day

Competition Type: NOT COMPETED

Number of Offers Received: 1

Pricing Type: FIRM FIXED PRICE

Sector: Healthcare

Official Description: NEW - STD PATHOGENS MOLECULAR TESTING REAGEANTS

Place of Performance

Location: FORT BRAGG, CUMBERLAND County, NORTH CAROLINA, 28310

State: North Carolina Government Spending

Plain-Language Summary

Department of Defense obligated $2.4 million to CEPHEID for work described as: NEW - STD PATHOGENS MOLECULAR TESTING REAGEANTS Key points: 1. Contract awarded on a sole-source basis, limiting price negotiation and potentially increasing costs. 2. Long contract duration of five years may not reflect current market needs or technological advancements. 3. Lack of competition raises concerns about value for money and potential for overspending. 4. Contract type (Firm Fixed Price) shifts risk to the government if costs escalate. 5. Geographic concentration in North Carolina for delivery. 6. No small business set-aside, potentially excluding smaller specialized firms.

Value Assessment

Rating: questionable

The contract's value is difficult to benchmark due to its sole-source nature. Without competitive bids, it's challenging to determine if the $2.4 million price represents a fair market value for molecular testing reagents. The firm fixed-price structure, while common, offers little flexibility if market prices for these reagents fluctuate significantly over the five-year period. The lack of transparency in pricing negotiations makes a definitive value assessment problematic.

Cost Per Unit: N/A

Competition Analysis

Competition Level: sole-source

This contract was awarded on a sole-source basis, meaning only one vendor, Cepheid, was solicited. This approach bypasses the standard competitive bidding process, which typically involves multiple vendors submitting proposals. While sole-source awards can be justified in specific circumstances (e.g., unique capabilities or urgent needs), they inherently limit price discovery and can lead to higher costs for the government.

Taxpayer Impact: The absence of competition means taxpayers may not benefit from the cost savings typically achieved through a competitive bidding process. This could result in a higher overall expenditure for these essential reagents.

Public Impact

Military personnel and beneficiaries will receive diagnostic testing services enabled by these reagents. Supports the Department of the Army's medical readiness and public health initiatives. Services are primarily delivered within North Carolina. Ensures availability of critical diagnostic tools for military healthcare facilities.

Waste & Efficiency Indicators

Waste Risk Score: 50 / 10

Warning Flags

Sole-source award limits price competition and may lead to higher costs.
Long contract duration could result in paying above-market rates if prices rise.
Firm Fixed Price contract shifts cost overrun risk to the government.
Lack of small business participation may limit access to innovative solutions.

Positive Signals

Ensures a consistent supply of critical molecular testing reagents.
Firm Fixed Price contract provides budget certainty for the awarded amount.
Supports a specific, identified need within the Department of the Army.

Sector Analysis

The market for in-vitro diagnostic substances, particularly molecular testing reagents, is a critical segment of the broader healthcare and life sciences industry. This sector is characterized by rapid technological advancements and significant R&D investment. Government contracts in this area often support national health security, military readiness, and public health initiatives. Benchmarking spending requires comparison to similar reagent procurements by other federal agencies or large healthcare systems, considering the specific types of tests and technologies involved.

Small Business Impact

This contract does not appear to include any small business set-aside provisions. The sole-source nature of the award further precludes opportunities for small businesses to compete or subcontract. This could limit the government's access to potentially innovative or cost-effective solutions that smaller, specialized firms might offer. The impact on the small business ecosystem is minimal in this specific instance due to the lack of competition.

Oversight & Accountability

Oversight for this contract would typically fall under the Department of the Army's contracting and program management offices. Accountability measures are inherent in the contract's performance requirements and delivery schedules. Transparency is limited due to the sole-source nature, with fewer public details available compared to competitively awarded contracts. Inspector General jurisdiction would apply if any fraud, waste, or abuse is suspected.

Related Government Programs

Medical Supplies and Equipment
Diagnostic Reagents and Kits
In-Vitro Diagnostic Devices
Military Medical Readiness

Risk Flags

Sole-source award
Lack of competition
Potential for price inflation
Long contract duration

Frequently Asked Questions

What is this federal contract paying for?

Department of Defense awarded $2.4 million to CEPHEID. NEW - STD PATHOGENS MOLECULAR TESTING REAGEANTS

Who is the contractor on this award?

The obligated recipient is CEPHEID.

Which agency awarded this contract?

Awarding agency: Department of Defense (Department of the Army).

What is the total obligated amount?

The obligated amount is $2.4 million.

What is the period of performance?

Start: 2021-10-01. End: 2026-09-30.

What is Cepheid's track record with government contracts, particularly for similar molecular testing reagents?

Information on Cepheid's specific track record with government contracts for molecular testing reagents is not detailed in the provided data. However, as a known manufacturer in this space, they likely have experience supplying similar products. A deeper dive would involve reviewing past performance evaluations, any contract disputes, and the volume/value of previous awards to assess their reliability and pricing history with federal agencies. Understanding their history with sole-source awards versus competitive bids would also be informative.

How does the $2.4 million contract value compare to market rates for similar molecular testing reagents?

Direct comparison to market rates is challenging without specific details on the exact reagents and quantities. However, the sole-source nature of this award raises concerns that the price may not be as competitive as it could be in a fully open market. Typically, sole-source contracts can be 10-30% higher than competitively bid ones. To accurately assess value, one would need to benchmark against prices paid by other agencies for comparable reagent types or consult industry price lists, adjusting for volume and contract terms.

What are the primary risks associated with a sole-source award for essential medical supplies?

The primary risks of a sole-source award for essential medical supplies include inflated pricing due to lack of competition, potential for reduced innovation as the contractor faces no competitive pressure, and supply chain vulnerabilities if the sole provider experiences disruptions. Taxpayers may bear a higher cost, and the government has less leverage to negotiate favorable terms. Furthermore, if the sole provider's technology becomes outdated, switching to a new vendor could be complex and costly.

What is the expected effectiveness of these molecular testing reagents in supporting military healthcare needs?

The effectiveness of these molecular testing reagents is expected to be high, assuming Cepheid's products meet the required quality and performance standards for diagnostic accuracy. These reagents are crucial for identifying various pathogens and conditions, directly supporting military healthcare readiness, force protection, and the health of service members and their families. Their specific application will depend on the types of tests they facilitate, ranging from infectious disease detection to other diagnostic purposes critical for military medical operations.

How has federal spending on molecular testing reagents trended over the past five years?

Federal spending on molecular testing reagents has likely seen a significant increase, particularly following the COVID-19 pandemic, which highlighted the critical need for rapid and accurate diagnostic capabilities. While specific aggregate data for this category isn't provided, broader trends in healthcare and defense spending on medical supplies suggest a growing demand. Factors influencing this trend include advancements in diagnostic technology, increased focus on infectious disease surveillance, and the ongoing need to support military health systems globally.

Are there alternative vendors or technologies that could fulfill this requirement, and why was Cepheid chosen on a sole-source basis?

The justification for choosing Cepheid on a sole-source basis would typically stem from unique technological capabilities, existing infrastructure compatibility, or urgent, unmet needs where no other vendor could provide a timely solution. Without the specific justification documentation, it's difficult to ascertain the precise reasons. However, potential alternatives might exist in the market, but they may not integrate seamlessly with existing military diagnostic systems or meet specific performance requirements as effectively as Cepheid's offerings, leading to the sole-source decision.

Industry Classification

NAICS: Manufacturing › Pharmaceutical and Medicine Manufacturing › In-Vitro Diagnostic Substance Manufacturing

Product/Service Code: INSTRUMENTS AND LABORATORY EQPT

Competition & Pricing

Extent Competed: NOT COMPETED

Solicitation Procedures: ONLY ONE SOURCE

Solicitation ID: W91YTZ21Q0105

Offers Received: 1

Pricing Type: FIRM FIXED PRICE (J)

Evaluated Preference: NONE

Contractor Details

Parent Company: Danaher Corporation

Address: 904 CARIBBEAN DR, SUNNYVALE, CA, 94089

Business Categories: Category Business, Corporate Entity Not Tax Exempt, Manufacturer of Goods, Not Designated a Small Business, Special Designations, U.S.-Owned Business

Financial Breakdown

Contract Ceiling: $3,064,454

Exercised Options: $2,475,674

Current Obligation: $2,398,990

Contract Characteristics

Commercial Item: COMMERCIAL PRODUCTS/SERVICES

Cost or Pricing Data: NO

Timeline